NCT06153615

Brief Summary

Idiopathic hypersomnia (IH) is a rare and poorly studied disease characterized by excessive daytime sleepiness different from that of narcolepsy (sleep drunkness non-recuperative naps and nocturnal blackout). Local sleep is a recent concept, proposing a local regulation of the sleep-wake state, characterized by slow waves (SW) restricted to certain regions of a globally awake brain. The investigators are going to investigate whether local sleep could explain the sleepiness of these patients better than the global occurrence of sleep which are not very frequent during daytime tests in IH. The investigators propose to look for local sleep through the detection of local slow waves in the EEG of resting wakefulness and during an attentional task in people with IH compared to people with NT1 (sleepy, but with a different type of sleepiness from IH, more abrupt and including REM sleep) and non sleepy people.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Dec 2023

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 29, 2023

Completed
2 months until next milestone

First Posted

Study publicly available on registry

December 1, 2023

Completed
Same day until next milestone

Study Start

First participant enrolled

December 1, 2023

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2024

Completed
Last Updated

December 1, 2023

Status Verified

November 1, 2023

Enrollment Period

Same day

First QC Date

September 29, 2023

Last Update Submit

November 29, 2023

Conditions

Keywords

Idiopathic HypersomniaNarcolepsia type 1

Outcome Measures

Primary Outcomes (1)

  • local sleep topography

    Density and topography of local sleep through the detection of local slow waves (SW) during resting wakefulness and during a daytime attentional test in IH, narcolepsy and healthy subjects

    At enrollment visit

Secondary Outcomes (3)

  • Daytime dynamics of local sleep

    At enrollment visit

  • behavioral implications of local sleep

    At enrollment visit

  • correlation between local sleep and behavioral marker of alertness

    At enrollment visit

Study Arms (3)

Idiopathic Hypersomnia

EXPERIMENTAL
Other: EEG (64 electrodes)Other: Cognitive task (SART)Other: Pupillometry and eye trackingOther: Thoracoabdominal belts

Narcolepsy type 1

ACTIVE COMPARATOR
Other: EEG (64 electrodes)Other: Cognitive task (SART)Other: Pupillometry and eye trackingOther: Thoracoabdominal belts

Healthy subject

ACTIVE COMPARATOR
Other: EEG (64 electrodes)Other: Cognitive task (SART)Other: Pupillometry and eye trackingOther: Thoracoabdominal belts

Interventions

EEG recording while awake, at rest then during an attentional cognitive test

Healthy subjectIdiopathic HypersomniaNarcolepsy type 1

Sustained attention go-no-go task (press a button each time a number is presented on a screen (1/second) except when the 3 appears) Assessment of mental status approximately every 45 seconds (task focus, mind wandering, mental blank, and sleepiness status)

Healthy subjectIdiopathic HypersomniaNarcolepsy type 1

Study of pupil size and gaze path during the cognitive test (correlated with alertness)

Healthy subjectIdiopathic HypersomniaNarcolepsy type 1

Abdominal and thoracic belts (used in all nocturnal polysomnographic recordings) for respiratory movement studies (correlated with sleepiness)

Healthy subjectIdiopathic HypersomniaNarcolepsy type 1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy subjects and people with IH and NT1:
  • \>18 years old, of both sexes, without legal protection.
  • Affiliated to the French social security system
  • Signature of free and informed consent
  • Fluency in spoken and written French
  • Specific to people with IH:
  • Diagnosis of IH according to the ICSD-3, already made in the sleep pathology department of the Pitié after a specialized medical interview and a standardized 48h assessment (Night 1+TILE+Night 2+two naps): Sleep time \> 660 min or TILE latency \<8 min, \<2 SOREMPs.
  • Specific to people with NT1:
  • Diagnosis of narcolepsy type 1 according to the ICSD-3, already made in the sleep pathology department of the Pitié after a specialized medical interview and a standardized 48h workup (Night 1+TILE+Night 2+two naps) and sometimes a lumbar puncture: hypocretin \<110 pmol/L in CSF or cataplexy and TILE latency \<8 min, \>1 SOREMP.

You may not qualify if:

  • Shift or night work
  • Sleep debt on the day of the recording (questioning and sleep diary one week before the recording)
  • Other sleep pathology causing daytime sleepiness (sleep apnea, insomnia, parasomnia for example)
  • Cerebral neurological pathology
  • Depressive episode
  • Any psychotropic treatment modifying the EEG structure
  • Failure to wean from arousing treatment on the day of the test.
  • Inability to travel by transport or to be transported by a relative on the day of the recording.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Pitié Salpêtrière

Paris, France

Location

MeSH Terms

Conditions

Idiopathic Hypersomnia

Condition Hierarchy (Ancestors)

Disorders of Excessive SomnolenceSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesMental Disorders

Study Officials

  • Isabelle Arnulf, MD, PhD

    Assistance Publique - Hôpitaux de Paris

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Isabelle Arnulf, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 29, 2023

First Posted

December 1, 2023

Study Start

December 1, 2023

Primary Completion

December 1, 2023

Study Completion

May 1, 2024

Last Updated

December 1, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

The data will be confidential until their publication in a peer reviewed journal. Sharing will be feasible after, in case of reasonable request to the PI.

Locations